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Abstract
The autophagy degradation pathway is a cellular pathway that sequesters cargo from
the cytosol to autophagosomes that are transferred to lysosomes for degradation or
recycled as  precursor  metabolites.  The  autophagy pathway allows the  removal  of
damaged  organelles/proteins  and  is  emerging  as  an  important  aspect  of  multiple
human pulmonary diseases. The autophagy process is important in both the function
of the immune system and the control of inflammation. Xenophagy (autophagy of
bacteria) is an example of selective autophagy which could play a role in host defense
mechanisms in pulmonary diseases such as sepsis. Autophagy pathways involving the
degradation of cytosolic cargo could play different roles in disease pathogenesis and
progression. In the case of certain lung diseases, mitophagy is elevated and the cilia
shorten  (ciliophagy),  which  contribute  to  lung dysfunction  in  the  pathogenesis  of
chronic  obstructive  pulmonary  disease.  In  other  types  of  lung  diseases  such  as
pulmonary vascular disease, autophagy may provide a protective role to allow cell
proliferation, repair and control of cell death. Disruption of autophagy in cystic fibrosis
and idiopathic pulmonary fibrosis could promote pathogenesis of the disease. In lung
cancer, autophagy is a ‘double-edged sword’ it blocks progression, but at the same
time promotes tumor growth. In this chapter, we will review the different types of
autophagy,  the  role  of  autophagy and its  significance  to  human lung diseases.  In
addition, we will discuss the potential of targeting autophagy with therapeutics for
lung disease management.
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1. Introduction
Autophagy is an evolutionarily-conserved cellular mechanism that allows the turnover of
organelles and proteins, through a lysosome-dependent degradation pathway in the cell. The
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most common type of autophagy (also called macroautophagy) involves the sequestering of
cytosolic  molecules  into double-membrane compartments  called autophagosomes,  which
subsequently  fuse  to  lysosomes  where  their  contents  are  degraded  and  recycled  into
metabolic precursors (Figure 1). Autophagy is emerging as an important mechanism in the
pathogenesis  of  several  pulmonary  diseases,  including  lung  injury,  sepsis,  pulmonary
vascular disease, idiopathic pulmonary fibrosis (IPF), cystic fibrosis and cancer. As autophagy
can act as a modulator of pathogenesis, it is a therapeutic target. A number of studies indicate
that  autophagy may provide a protective function against  disease and at  the same time
contribute  to  deleterious  processes,  usually  when  its  activity  is  impeded  or  elevated.
Autophagy is a known function in the clearance of subcellular material and the recycling of
metabolites playing a role in cellular detoxification and adaptive or protective mechanisms.
It is well accepted that autophagy plays a key role as a regulator of adaptive and innate
immune responses, hence modulating autophagy could have a profound effect on disease
pathogenesis. Xenophagy, which is the autophagic clearance of pathogens/bacteria, is one of
the host’s protective defense mechanisms against the pathogenesis of sepsis and inflammatory
diseases. However, autophagy clearance of mitochondria may contribute to chronic obstruc-
tive pulmonary disease (COPD) through the activation of cell death pathways. In other types
of  pulmonary  diseases,  impairment  of  autophagy  may  aggravate  and  contribute  to  the
pathogenesis  process.  In  contrast,  active  autophagy  in  lung  cancer  could  have  many
consequences including controlling carcinogenesis, modulating treatment efficacy and thus
supporting tumor cell survival.
Figure 1. Schematic of the steps of autophagy. In the first step of autophagy the isolation membrane or phagophore is
formed. In the next step of vesicle elongation, the proteins of the autophagy core machinery are believed to gather at
the phagophore assembly site (PAS), and expand the phagophore into an autophagosome. In the next step, the auto-
phagosome can engulf the cytosolic cargo including targeted cargo/organelles specifically. Following engulfment of
cargo, the autophagosome can fuse with an endosome called an amphisome (not shown) or directly fuse with a lyso-
some to form an autophagolysosome. In the final step the cargo inside the autophagolysosome is degraded and free
metabolites recycled.
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2. Autophagy regulation
The autophagy process is comprised of the rearrangement of membrane components derived
from the endoplasmic reticulum (ER), the endosome/Golgi, plasma membrane and mitochon-
drial membranes [1–9]. Autophagy proceeds through several sequential steps (Figure 1),
starting with the formation of the phagophore or the isolation membrane at the preautopha-
gosome site (PAS, see Figure 1) [10]. Next, the autophagic membrane elongates forming a
double-membrane autophagosome engulfing a part of the cytoplasm. The maturation of the
autophagosome and its cargo results in their fusion with the lysosome to form a single-
membrane compartment, the autolysosome. This process is assisted by many proteins such as
class C Vps proteins, small GTPases (e.g., Rab5 and 7), UVRAG and lysosome-associated
membrane proteins (e.g., LAMP2) [11–14]. The cargo can then be degraded through the action
of lysosomal degradative enzymes such as acid hydrolases that are activated at low pH (pH
5). This is accomplished by a proton pump located in the lysosomal membrane pumping H+
ions from the cytosol into the lysosome [15]. The degraded products such as free amino acids,
nucleotides and fatty acids are then released into the cytoplasm by lysosomal permeases and
then recycled through anabolic pathways [10].
A large number of autophagy-related (Atg) proteins regulate autophagy through various steps
of initiation and execution [16, 17]. Autophagy is regulated by upstream cellular signals such
as glucose or amino acid starvation and is an adaptive response in these conditions [10].
Autophagy contributes to cellular homeostasis along with the unfolded protein response
(UPR) and endoplasmic reticulum stress (ERS). All these cellular responses are linked through
crosstalk and can be activated by external stimuli such as hypoxia [18]. The mammalian target
of rapamycin complex 1 (mTORC1) and the energy sensing, 5′-adenosine monophosphate-
regulated kinase (AMPK) are the main regulators initiated under starvation conditions. The
mammalian target of rapamycin (mTOR) pathway suppresses autophagy under starvation
conditions can be activated by growth factors through the Class I phosphatidylinositol-3-
kinase (PI3K)/Akt-pathway [19]. As well as mTOR protein, mTORC1 is comprised of the
regulatory-associated protein of mTOR (Raptor), the mammalian lethal with SEC13 protein 8
(mLST8), and the 40 kDa proline-rich Akt/PKB substrate (PRAS40) [17]. mTORC1 can be
inhibited by rapamycin or starvation leading to autophagy activation via derepression of the
substrate complex, the uncoordinated 51-like kinase-1 (ULK1) complex, which is comprised
of ULK1, FIP200/RB1CC1, Atg13 and Atg101 [20–24]. Upregulation of AMPK is directly related
to an increase in AMP levels which inturn downregulates mTORC1 by Raptor phosphorylation
and in addition activates ULK1 [25, 26]. A recent study has shown that the trafficking of mAtg9
which is involved in vesicle delivery to the PAS is regulated by AMPK-dependent ULK1
phosphorylation [27].
The Beclin1 complex is comprised of Beclin1, class III PI3K (PI3KC3/Vps34), UVRAG or p150
and Atg14L [28, 29]. The connection of ULK1 and Beclin 1 complex regulation via Vps34
phosphorylation has been demonstrated [30, 31]. Also, Beclin 1 complexes are known to
associate with a number of inhibitory or activating proteins such as Ambra 1 [28]. Autopha-
gosome formation requires the activation of PI3KC3 in the Beclin 1 complex leading to the
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formation of phosphatidylinositol-3-phosphate (PI3P). Various accessory protein factors are
recruited by PI3P such as the double FYVE-containing protein-1 (DFCP1) and the WD-repeat
protein in association with phosphoinositides (WIPI) proteins that are important in the
assembly of autophagosomes [20, 32, 33]. In addition, the soluble N-ethylmaleimide-sensitive
factor attachment protein receptor (SNARE) proteins are also implicated recruitment of
membrane and the assembly of autophagosomes [34, 35].
There are two ubiquitin-like conjugation systems: the LC3/ATG8 conjugation system and the
ATG5–ATG12 conjugation system [36]. Autophagosome assembly requires ATG5–ATG12
conjugates along with ATG16L1. The ubiquitin-like protein microtubule-associated protein-1
light chain 3 (LC3B) mediates autophagosome formation [17]. The pro-LC3 form is cleaved by
the endopeptidase, ATG4B generating LC3B-I form. In eukaryotes, LC3B-I (unconjugated
form) conversion to its conjugated phosphatidylethanolamine (PE) form, and the association
of LC3B-II with the membrane is an important stage of autophagosome biogenesis [36, 37].
LC3B-II association with the autophagosomal membrane is prolonged until the final stages of
autophagosome-lysosome fusion. At the final stages, the LC3B-II associated with the outer
membrane can be recycled by ATG4B while LC3B-II found on the inner membrane will be
degraded by lysosome degradative enzymes [17].
3. Autophagy
3.1. Lung injury
Acute lung injury (ALI) is characterized by an uncontrolled acute inflammation and dysfunc-
tion of both the endothelial and epithelial barriers in the lung, and disproportionate transepi-
thelial leukocyte migration, affecting the integrity of the alveolar-capillary membrane and the
increase of proinflammatory cytokines [38–40]. In addition, ALI is linked to hyperoxia, sepsis,
trauma, xenobiotic exposure and mechanical ventilation.
The annual incidence of ALI in the USA in 2005 was around 78.9 per 100,000 [41]. However,
current ALI therapy is fairly basic involving simple medical or surgical treatment allowing an
improvement in ventilation of the patient, while remedial ALI therapy exists [39, 42, 43]. The
ALI pathogenesis can be rationalized by the injury to both the alveolar epithelium and vascular
endothelium. The innate immune system cells are both the target of damage and effectors of
injury in ALI/acute respiratory distress syndrome (ARDS). Damage to type I alveolar epithelial
cells promotes pulmonary edema and the degradation of the epithelial layer revealing the
basement membrane increasing the chances of bacteremia and sepsis. Damage of type II
alveolar cells results in perturbed synthesis of surfactant and metabolism giving rise to
elevated alveolar surface tension and alveolar collapse [38]. A diverse range of biomarkers
such as intracellular adhesion molecule-1 (ICAM-1), the receptor for advanced glycation end-
products (RAGE), von Willebrand factor (vWf) and surfactant D (SP-D) have been discovered
in the endothelium and the epithelium; these play a role in coagulation cascades and inflam-
mation and may be used to predict outcome in patients with ALI [44–47]. In addition, aberra-
tions in the coagulation cascade as a result of plasminogen activator inhibitor-1 and protein C
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also contribute to ALI [48]. Furthermore, the elevated levels of the inflammatory factors such
as interleukins (IL-1, -6, -8) and tumor necrosis factor (TNF) are often associated with a
response to cellular injury [49, 50].
Autophagy has been implicated in the pathogenesis of ALI [51] but could be due to long
exposure to high levels of oxygen (hyperoxia) through mechanical ventilation treatment.
Hyperoxia is sufficient to induce autophagy activation and LC3B knockdown effects cell
survival [51]. Further studies have shown that in normal physiological conditions, the
formation of a complex, p62/LC3B/truncated BH3-interacting domain death agonist (tBID) is
necessary for cellular homeostasis [52]. In hyperoxia conditions, this complex dissociates and
prevents the transport of tBID to the lysosome. The elevated levels of tBID result in the
mitochondria releasing cytochrome c and caspase-dependent cell death [52]. The outcome of
hyperoxia can lead to mitochondrial dysfunction in the lungs [53, 54]. Thus, mitophagy in
hyperoxia has been implicated to play a role in ALI pathogenesis [55].
3.2. Infectious lung disease
Phagocytosis can act against infection in two ways: by ingesting bacteria (by macrophages and
neutrophils) or by processing infectious agents for antigen presentation by dendritic cells.
Similarly, autophagy is emerging as an essential process in innate and adaptive immune
functions [56]. Autophagy plays an important role in protection of the host from various
microbes such as viruses, bacteria and parasites [56–58]. The functions of antibacterial and
antipathogenic autophagy are well characterized [59, 60]. It is known that phagocytosis of
nonpathogenic mycobacteria by macrophages stimulates autophagy and apoptosis resulting
in the removal of the pathogen. Conversely, the phagocytosis of pathogenic mycobacteria can
perturb the autophagy pathway [61].
Tuberculosis is the result of a pathogen infection called Mycobacterium tuberculosis which is a
serious infection affecting the lungs and is a burden worldwide [62]. The mycobacteria are
resistant, remaining and replicating inside the immature phagosomes during tuberculosis
infection. M. tuberculosis utilizes a protective survival strategy which allows them to interfere
with a fusion event at the phagosomal compartments comprising M. tuberculosis and lyso-
somes [63]. Furthermore, the M. tuberculosis phagocytosis stimulates necrotic cell death
allowing mycobacteria release to uninfected cells as opposed to stimulating macrophage
apoptosis. Thus, this leads to a reduction in mycobacterial antigen presentation and promo-
tion of M. tuberculosis infection [64]. The intracellular survival and replication rate of M.
tuberculosis can be reduced through stimulation of autophagy [59, 60, 64–66]. Recent studies
have shown that several compounds that stimulate autophagy through mTORC1 inhibition
to alleviate M. tuberculosis infection [67, 68]. At the same time, autophagy inhibition promotes
M. tuberculosis infection [60].
Autophagy can be important for antivirulence elements against M. tuberculosis generated
substrate degradation [69, 70]. The host defense system against M. tuberculosis is protected by
the production of interferon-gamma (IFN-γ) which stimulates macrophages, induces the
autophagy process and thus protects the host against infection [60, 69]. In fact, stimulating
with IFN-γ leads to bacteria degradation by p62-dependent selective autophagy [69]. Autoph-
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agy induced by IFN-γ requires p47 guanosine triphosphatase IRGM-1 [60, 71, 72] and increased
sensitivity to M. tuberculosis infection is associated with single nucleotide polymorphisms in
the IRGM-1 gene [73].
M. tuberculosis processing has been recently linked to selective autophagy [74]. It is known that
the bacterial early secretory antigenic target (ESAT-6) system 1 (ESX-1) secretion system
facilitates phagosomal permeabilisation allowing the ubiquitin-mediated autophagy entry to
phagosomal M. tuberculosis. The extracellular bacterial DNA is recognized and tagged with
ubiquitin by the stimulator of interferon gene (STING)-dependent cytosolic pathway. Then p62
and NDP52, the autophagy cargo adaptors, recognize ubiquitinated M. tuberculosis and target
them to autophagosomes.
Autophagy is also described as a defense mechanism against other pathogens affecting the
respiratory system. The growth of Legionella pneumophila which causes Legionnaire’s disease
is promoted in the absence of Atg9 suggesting that autophagy contributes to defense against
this pathogen [75]. Influenza-A virus infection induces autophagy and autophagosome
formation is necessary for virus replication [76], but it is believed that the influenza-A proteins
such as M2 protein, can block autophagosome formation and subsequent fusion with the
lysosome [77]. Recent studies on influenza infection have shown that autophagy is a requisite
for maintaining memory B cells that are necessary in secondary antibody responses. Mice
carrying a B cell-specific knockout of Atg7 showed perturbed secondary antibody responses
and thus were more sensitive to influenza infection [78]. Therefore, future therapeutic
developments should challenge the modulation of the autophagy pathway to eliminate
infection and encourage adaptive immunity against infectious agents.
3.3. Emphysema and chronic obstructive pulmonary disease
Emphysema is characterized by the deterioration of the lung parenchyma as a result of an
abnormal inflammatory response. In addition, there is degradation of the pulmonary matrix
leading to an increase in the lung space and reduced respiratory function [79]. It is commonly
observed that mice exposed to cigarette smoke give rise to an increase in lung space and can
be used as a model of emphysema. Mice exposed to cigarette smoke over 3 months demonstrate
raised autophagosomal numbers and elevated levels of LC3B-II in the resected lung tissue [80].
Interestingly, in the LC3B knockout mouse model demonstrated insensitivity to cigarette
smoke leading to no change in the lung space. Depletion of the early growth response-1 (Egr-1)
known to regulate LC3B transcription resulted in an increase in lung space with no changes
induced with cigarette smoke. Conversely, knockout of caveolin-1 in mice led to sensitivity to
cigarette smoke [80, 81]. Thus, LC3B is considered to be a crucial regulator of apoptosis and
autophagic signaling.
Chronic obstructive pulmonary disease (COPD) is emerging as a global burden to society [82].
COPD is clinically defined into different types of lung disease, including emphysema and
bronchitis leading to obstruction of the airway with mucus [83]. The main risk factor for COPD
is cigarette smoke [84]. The mechanisms of COPD pathogenesis are still unknown. However,
some theories indicate that abnormal cellular and inflammatory responses to cigarette smoke
within the lung, the vessels and the airspace may be involved [84, 85]. The role of autophagy
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in COPD pathogenesis could be demonstrated by an excessive increase in autophagy or by
mitophagy (selective degradation of mitochondria by autophagy) leading to cell death [80, 81,
86–88]. These studies indicate that the levels of the autophagy markers (such as LC3-II) and
the mitophagy markers (such as PINK1) are elevated in COPD patient’s lung tissue. Thus, an
increase in autophagy or a defect in the autophagy flux could contribute to COPD pathogen-
esis [80, 87, 89]. In fact, a number of studies have shown that cigarette smoke can induce
abnormal autophagy and mitophagy leading to bronchial cell death through apoptosis or
necroptosis, respectively [81, 87]. Furthermore, there was an increase in histone deacetylase-6
levels as a result of oxidative stress, inducing hypomethylation leading to autophagy and cilia
shortening which could contribute to mucociliary dysfunction [86]. Previous studies have
shown that a block in autophagy promotes cilia growth [90]. Cigarette smoke has been shown
to activate autophagy leading to elevated cell senescence along with a build-up of both p62
and ubiquitinated proteins [91]. As a result of autophagy blockade, cells display a ‘senescence-
associated secretory phenotype’ secreting interleukin 8 (CXCL8) [91]. Autophagy was rescued
with Torin 1, an mTOR inhibitor [91]. The genetic knockout Atg5−/− mouse model showed that
p62 levels were elevated in the lung epithelial cells along with a shortening of cilia [92].
A recent study analyzing autophagy in macrophages in the alveoli from smokers’ lung showed
induction of LC3-II and the presence of autophagosomes [93]. The levels of autophagosomes
in macrophages were elevated and autophagy activity was perturbed [93]. Altogether, these
studies implicate that autophagy is an important cellular process in COPD pathogenesis.
Future studies will need to address whether cigarette smoke promotes or blocks the autophagy
flux in lung parenchyma, as well as the links between autophagy, apoptotic cell death and
development of emphysema.
3.4. Pulmonary vascular disease
Hypoxia is an important contributing factor to pulmonary cardiovascular diseases such as
pulmonary hypertension (PH), ischemia-reperfusion injury and atherosclerosis [94]. The
hypoxia-inducible factors (HIFs), heterodimers of transcription family Per-Arnt-Sim/basic
helix-loop-helix, regulate hypoxia. The heterodimer of HIF-1 is composed of two subunits,
HIF-1β and HIF-1α, the O2-sensitive subunit. Under normoxia conditions, HIF-1α is degraded
by the proteasome aided by HIF prolyl hydroxylase and the von Hippel-Lindau E3 ubiquitin
ligase [94].
It is widely reported that the autophagy process can be regulated by hypoxia in cells and
tissues. This process could be a crucial factor in cell injury induced by hypoxia in mitochondrial
turnover [95–98]. Under in vitro conditions, autophagy activation requires Beclin 1 and an
element that can be induced, encompassing HIF-1α stabilization and elevated ROS produc-
tion [67, 96]. In addition, hypoxia-inducible autophagy is regulated by BNIP3 (Bcl-2/adenovi-
rus E1B 19 kDa-interacting protein-3), a Bcl-2 family member [96].
The accumulation of abnormal, unfolded proteins during hypoxia or nutrient deprivation
(endoplasmic reticulum stress, ERS) is the stimulus for the unfolded protein response. In its
adaptive phase, this vital defense mechanism initially recruits autophagy to assist ER-
associated degradation in the breakdown of abnormal proteins, while blocking cell death
The Role of Autophagy in Lung Disease
http://dx.doi.org/10.5772/64167
273
pathways. This prosurvival role for autophagy is partly responsible for resistance of hypoxic
cells to therapies, such as chemotherapy [18]. Autophagy activation in tumor cells through
hypoxia requires BNIP3 [97, 98]. In this case, autophagy could provide a mechanism of cell
survival in hypoxia conditions via selective mitophagy [96]. It still remains unclear how BNIP3
acts during hypoxia either through cell survival or the cell death pathway.
Hypoxia conditions trigger autophagy in pulmonary vascular primary cells. In particular,
hypoxia experiments performed in vitro show that LC3B-II accumulates and Beclin 1 expres-
sion increases both in pulmonary vascular endothelial cells and muscle cells. In addition, GFP-
LC3 puncta are formed which is a common feature of autophagosome formation in cells
transfected with GFP-LC3 [95]. In the same study, LC3-II and autophagosome formation were
elevated in the presence of the autophagosomal inhibitor, bafilomycin A1, indicating elevated
autophagic activity [95].
3.5. Idiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosis (IPF) is characterized by the build-up of extracellular matrix
proteins deposited in the interstitial tissue and basement membrane of damaged epithelium
and an increase in active mesenchymal cells such as myofibroblasts [99]. The lung interstitium
is primarily composed of fibroblasts, which play a role in maintaining the extracellular matrix
and in wound healing. Altered autophagic function is implicated in the pathogenesis of IPF.
Elevated cellular senescence and decreased autophagy activity as a result of decreased LC3B
protein expression have been observed in the lung tissues from patients with IPF and in lung
fibroblasts treated with TGF-β [91, 100]. TGF-β1 is known as an inhibitor of autophagy in
human lung fibroblasts. In fibroblasts, genetic ablation of the autophagy proteins, LC3B or
Beclin1, elevates the expression of fibronectin and α-smooth muscle actin (a myofibroblast
marker) induced by TGF-β1 [100]. The mTORC1 inhibitor, rapamycin, was shown to protect
against lung fibrosis when mice were treated [100]. Thus, reduced autophagy in IPF patients
could increase the efficacy of TGF-β1 leading to a build-up of the extracellular matrix and
conversion to a myofibroblast phenotype. Perturbation of lung IL-17A has been demonstrated
to be protective against fibrosis, through autophagy recovery, in a mouse bleomycin model of
pulmonary fibrosis [101]. Recent studies have shown that the multiple tyrosine kinase inhibitor
nintedanib downregulated extracellular matrix production and promoted autophagy in IPF
fibroblasts while inhibiting the TGF-β signaling pathway [102]. However, further investiga-
tions are required to better understand the role of autophagy and the molecular mechanism
of fibrogenesis.
3.6. Cystic fibrosis
CF is a fatal genetic lung disease caused by a mutation in the gene encoding the cystic fibrosis
transmembrane conductance regulator (CFTR); it is characterized by the accumulation of
mucus in the airways. This accumulation can result in damage to the lungs that are linked to
recurrent secondary infections. The CFTR mutation of a deletion of phenylalanine at position
508 (CFTRF508del) is the most common found in humans [103]. Recent studies are demon-
strating defective autophagy with the CFTR mutation in airway epithelial cells from CF
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patients with the CFTR mutation. This is visualized by a reduction in autophagosome number
along with the presence of LC3 puncta and p62 accumulation in starvation conditions [104].
Cells expressing CFTR F508del have been shown to be defective in autophagy and to accu-
mulate polyubiquitinated proteins and aggresome-like structures [105]. Inflammatory
response is enhanced in CF with defective autophagy [106]. In addition, defective CFTR can
upregulate reactive oxygen species production and tissue transglutaminase [104]. A block in
autophagy leads to cross-linking and inactivation of Beclin1 with PI3KC3 sequestering and
p62 accumulation [104]. Protein trafficking of CFTR F508del to the cell surface could be restored
with the overexpression of Beclin1 or the depletion of p62 [104]. Targeting p62 genetically
rescued the functional expression of CFTR and improved the efficacy of CFTR channel
activators [107]. Genetic targeting of p62 was also recently shown to improve the therapeutic
effect of CFTR channel activators [107].
Xenophagy, the clearance of bacteria by autophagy, could play a role in defending against
infections linked to CF. In a mouse CF model, rapamycin has been shown to alleviate Burkhol‐
deria cenocepacia infection and reduce lung inflammation [108]. In vivo studies have shown that
pharmacological intervention of autophagy could enhance the clearance of Pseudomonas
aeruginosa bacteria from the lung [109]. Therefore, dysfunctional autophagy leading to a
compromise as a result secondary infection could promote CF pathogenesis. Hence, future CF
therapy should include the rescue of autophagy [110].
3.7. Cancer
The autophagy pathway is a complex biological process that is believed to influence the
induction, development and cancer therapy. Autophagy is the main cellular protection system
with an anticarcinogenic effect through preserving mitochondria, recycling of precursors of
metabolism, removal of cell debris/products and the control of inflammation that could
promote gene instability [111]. Surprisingly, autophagy could provide a mechanism that
contributes to tumor cell survival and cancer progression as a result of chemotherapy resist-
ance. At the same time, autophagy could provide a means to treat the cancer through chemo-
therapy promoting autophagy-mediated cell death [111].
Early studies demonstrated that the monoallelic loss of Beclin1 from chromosome 17q21 occurs
in many cancers such as prostate, breast and ovarian [112–114]. It is reported from in vitro
studies that perturbing autophagy can promote cancer growth, and in addition heterozygous
Beclin1 mice develop lung, liver and lymphomas [115, 116]. In addition, the aberrant expres-
sion of Beclin1 in the tumor is associated with poor outcome and aggressive disease [57, 58].
Currently, the role of autophagy in the lung and its effect on therapy is an unexplored area of
research. Studies have shown that Beclin1 expression is reduced in NSCLC compared to
healthy tissue and this reduction is further pronounced in higher stage, poorly differentiated
tumors [117, 118]. Autophagy induction with mTOR inhibitors is linked to radiosensitization
in NSCLC [119]. In addition, hydroxychloroquine, an autophagy inhibitor, has been tested in
the clinic for treatment of NSCLC on the basis that inhibition of autophagy, which aids cell-
survival, helps prevent resistance to chemotherapy [113]. Depletion of the autophagy protein,
ATG5, both perturbs the progression of KRas (G12D) lung cancer and stimulates tumor
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survival in a mouse model. On the other hand, ATG5 depletion promotes the initiation of KRas
(G12D) tumors [120]. These studies indicate the ‘double-edged sword of autophagy’ in cancer
where autophagy prevents progression and promotes tumor growth.
4. Conclusion and future perspectives
It is emerging that autophagy can promote and perturb pathogenesis in human disease (see
Figure 2). These effects are well illustrated in cancer, where the ‘double-edged sword’ of
Figure 2. The effects of autophagy in human lung diseases. The role of different pathways of autophagy to remove
bacteria (xenophagy), mitochondria (mitophagy), cilia (ciliophagy) and protein aggregates (aggrephagy). The autopha-
gy process plays a role in the pathogenesis of many human lung diseases as shown in the schematic. In lung cancer,
autophagy could perturb tumorigenesis, but at the same time promote cell proliferation and thus tumoral survival. In
pulmonary infections, autophagy could reduce bacterial expansion and block survival of bacteria such as M. tuberculo‐
sis. The pathogenesis of human lung disease is promoted with cigarette smoke exposure which induces oxidative stress
and triggers cilia protein damage.
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autophagy provides protection in the early stages of disease, while in the later stages promotes
tumor growth or resistance to therapy. In some lung diseases, such as sepsis, autophagy could
provide protection against bacterial infection and allow an inflammatory response. In the case
of exposure to cigarette smoke, this aggravates and promotes disease progression for many
human lung diseases. Current therapeutic strategies are still in development, and a few
molecules that regulate autophagy have already been tested in the clinic. For example, the
autophagy inhibitors chloroquine and hydroxychloroquine and autophagy inducer, mTOR
inhibitor rapamycin, have been analyzed in the clinic. Recent development of compounds that
modulate autophagy has been the Tat-Beclin 1 peptide, an inhibitor of histone deacetylases
[121], vitamin D and AMPK activators [58, 113, 122]. Due to the complexity of autophagy,
further research is required to fully understand how modulating autophagy could be used as
a therapeutic strategy in disease management. In addition, we will need to define the various
pathways of selective autophagy and their relevance to disease pathogenesis. This will allow
the design of novel compounds to be used in therapeutic strategies that could specifically target
certain lung diseases.
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